

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

百奥赛图(北京)医药科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2315)

POLL RESULTS OF THE 2023 FIRST EXTRAORDINARY GENERAL MEETING, THE 2023 FIRST CLASS MEETING OF H SHAREHOLDERS AND THE 2023 FIRST CLASS MEETING OF DOMESTIC AND UNLISTED SHAREHOLDERS HELD ON 20 APRIL 2023

References are made to the circular of (the “**Circular**”) of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (百奥赛图(北京)医药科技股份有限公司) (the “**Company**”) incorporating, among others, the notices (the “**Notices**”) of the 2023 first extraordinary general meeting (the “**EGM**”), the 2023 first meeting of H shareholders (the “**Class Meeting of H Shareholders**”) and the 2023 first class meeting of domestic and unlisted shareholders (the “**Class Meeting of Domestic and Unlisted Shareholders**”, together with Class Meeting of H Shareholders, the “**Class Meetings**”) dated 31 March 2023. Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Circular.

The Board hereby announces that (i) the EGM, (ii) the Class Meeting of H Shareholders and (iii) the Class Meeting of Domestic and Unlisted Shareholders (collectively, the “**Meetings**”) were held with the combination of a physical meeting at the conference room of 12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, PRC and a virtual meeting online on Monday, 20 April 2023 at 10:00 a.m.. The Meetings were held in accordance with the requirements of the PRC Company Law and Articles.

As at the date of the EGM and Class Meetings, the total number of issued shares of the Company was 399,398,420, comprising 110,781,920 H Shares and 288,616,500 Domestic and Unlisted Shares. To the best knowledge, information and belief of the Company, save for that Shareholders listed in the “I. CONVENING OF THE MEETINGS - (1) EGM” who have interest in the issue mentioned in the resolution numbered 13, collectively holding 42,942,780 H Shares and 263,100,780 Domestic and Unlisted Shares, shall abstain from voting in the resolution numbered 13 at the EGM, (1) there were no Shares entitling the holder to attend and abstain from voting in favor of the resolutions proposed at the EGM and Class Meetings as set out in rule 13.40 of the Listing Rules; (2) no Shareholder was required under the Listing Rules to abstain from voting on the resolutions proposed at the EGM and Class Meetings; and (3) no party has stated any intention in the Circular to vote against or to abstain from voting on any of the resolutions proposed at the EGM and Class Meetings. All resolutions were put to vote by way of poll.

Dr. Shen Yuelei, Chairman of the Company, acted as the chairman of the Meetings and presided over the Meetings. All the Directors, the Supervisors, as well as the secretary of the Board were present at the Meetings either in person or by means of telecommunication.

I. CONVENING OF THE MEETINGS

The attendance of the EGM and Class Meetings is as follows:

(I) EGM

For the resolution numbered 13, Dr. Shen Yuelei and Dr. Ni Jian and their controlled corporations (Note 1), collectively holding 16,854,300 H Shares and 93,240,540 Domestic and Unlisted Shares, were required under the Listing Rules to, and had, abstained from voting on the resolution numbered 13 at the EGM. In addition, as (i) State Development & Investment Group Co., Ltd. (“SDIC”) and its controlled corporations (Note 2), collectively holding 72,937,440 Domestic and Unlisted Shares; (ii) China Merchants Bank Co., Ltd. (“CMBC”) and its controlled corporations (Note 3) collectively holding 26,088,480 H Shares and 51,171,840 Domestic and Unlisted Shares; (iii) China Life Chengda (Shanghai) Healthcare Equity Investment Management Company Limited, holding 14,296,320 Domestic and Unlisted Shares; (iv) Jiangsu China Life Jiequan Equity Investment Center (Limited Partnership), holding 9,222,840 Domestic and Unlisted Shares; (v) PICC Beijing Health Care Fund, L.P., holding 9,222,840 Domestic and Unlisted Shares; (vi) Shenzhen Zhaoyin Gongying Equity Investment Partnership (Limited Partnership), holding 1,355,760 Domestic and Unlisted Shares; (vii) Zhuhai Growth Win-Win Venture Capital Fund (Limited Partnership), holding 2,459,520 Domestic and Unlisted Shares; and (viii) Beijing Yuanqing Bencao Equity Investment Center (Limited Partnership), holding 9,193,680 Domestic and Unlisted Shares are investors of a related party contemplated under the resolution numbered 13, such parties had abstained from voting on the resolution numbered 13 at the EGM as advised by the Company's PRC legal advisors. The total Shares entitling the holders to attend and vote on the resolution numbered 13 and other resolutions proposed at the EGM were 93,354,860 and 399,398,420 respectively. The total number of Shares with voting right, on the resolution numbered 13 and other resolutions, represented by the Shareholders attending the EGM in person or by proxy was 63,636,140 and 369,679,700 representing 68.2% and 92.6% of the total number of Share with voting rights, respectively.

Note 1: Beijing Baiao Evergreen Technology Development Center (Limited Partnership)* (北京百奧常青科技發展中心(有限合夥)), Beijing Baiao Changsheng Technology Development Center (Limited Partnership)* (北京百奧常盛科技發展中心(有限合夥)), Beijing Eucure Evergreen Technology Development Center (Limited Partnership)* (北京祐和常青科技發展中心(有限合夥)) and Beijing Eucure Changsheng Technology Development Center (Limited Partnership)* (北京祐和常盛科技發展中心(有限合夥)).

Note 2: State Development & Investment Corporation (SDIC) VC Fund (Ningbo) of Technology Transfer and Commercialization (Limited Partnership), State Development & Investment Corporation (SDIC) VC Fund (Shanghai) of Technology Transfer and Commercialization (Limited Partnership), State Development & Investment Corporation (SDIC) Gaoxin (Shenzhen) VC Fund (Limited Partnership).

Note 3: Astral Eminent Limited, Zhaoyin Chengzhang Qihao Investment (Shenzhen) Partnership (Limited Partnership) (招銀成長柒號投資(深圳)合夥企業(有限合夥)), Shenzhen Zhaoyin Langyao Growth Equity Investment Fund Partnership (L.P.) (深圳市招銀朗曜成長股權投資基金合夥企業(有限合夥)), Zhaoyin Chengzhang Shijiu hao Equity Investment Fund Partnership (Limited Partnership) (深圳市招銀成長拾玖號股權投資基金合夥企業(有限合夥)) and CMB International Capital Management (Shenzhen) Co., Ltd. (招銀國際資本管理(深圳)有限公司).

(II) Class Meeting of H Shareholders

The total number of H Shares entitling the holders to attend and vote on the resolutions at the Class Meeting of H Shareholders was 110,781,920. H Shareholders and proxies of H Shareholders who attended the Class Meeting of H Shareholders held a total of 81,063,200 H Shares with voting rights, representing approximately 73.2% of the total number of H Shares with voting rights.

(III) Class Meeting of Domestic and Unlisted Shareholders

The total number of Domestic and Unlisted Shares entitling the holders to attend and vote on the resolutions at the Class Meeting of Domestic and Unlisted Shareholders was 288,616,500. Domestic and Unlisted Shareholders and proxies of Domestic and Unlisted Shareholders who attended the Class Meeting of Domestic and Unlisted Shareholders held a total of 288,616,500 Domestic and Unlisted Shares with voting rights, representing approximately 100.0% of the total number of Domestic and Unlisted Shares with voting rights.

II. POLL RESULTS OF THE MEETINGS

(I) Poll Results of the EGM

The poll results of the EGM were as follows:

Special Resolutions	Number of valid votes and percentage of total votes (%)			Passed by Shareholders
	For	Against	Abstain	
1. To consider and approve the proposed issue of A shares (the “Issue of A Shares”) as follows (each and every items as a separate resolution)				
i. Class of new Shares to be issued;	369,679,700 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
ii. Place of listing;	369,679,700 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
iii. Nominal value of new Shares to be issued;	369,679,700 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
iv. Issue size;	369,679,700 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
v. Target subscribers;	369,679,700 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
vi. Method of issuance;	369,679,700 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
vii. Method of underwriting;	369,679,700 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
viii. Pricing methodology;	369,679,700 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
ix. Schedule of issuance;	369,679,700 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
x. Use of proceeds;	369,679,700 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
xi. Validity period of the resolutions	369,679,700 (100.00%)	0 (0.00%)	0 (0.00%)	Yes

Special Resolutions	Number of valid votes and percentage of total votes (%)			Passed by Shareholders
	For	Against	Abstain	
2. To consider and approve the authorization the Board of Directors and persons authorized by it to fully handle relevant matters in connection with Issue of A Shares and listing on the Sci-Tech Board;	369,679,700 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
3. To consider and approve the investment projects to be funded by the proceeds raised from the Issue of A Shares and feasibility analysis (each and every items as a separate resolution):				
i. Drug early development service platform construction project	369,679,700 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
ii. Antibody drug development and evaluation project	369,679,700 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
iii. Preclinical and clinical development	366,742,820 (99.21%)	0 (0.00%)	2,936,880 (0.79%)	Yes
iv. Supplementary working capital	369,679,700 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
4. To consider and approve the proposal for the plan for undertaking accumulated unrecovered losses prior to the Issue of A Shares;	369,679,700 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
5. To consider and approve the share price stabilization plan within three years after the Company's initial public offering of A Shares and listing on the Sci-Tech Board;	369,679,700 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
6. To consider and approve the three-year dividend distribution plan for Shareholders after the initial public offering of A Shares and listing on the Sci-Tech Board;	369,679,700 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
7. To consider and approve the impact of dilution on immediate return by the initial public offering of A Share and recovery measures for the immediate return;	369,679,700 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
8. To consider and approve the undertakings and restraining measures relating to Issue of A Shares and listing on the Sci-Tech Board;	369,679,700 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
9. To consider and approve the proposed amendments to the Articles in respect of Issue of A Shares;	369,651,700 (99.99%)	28,000 (0.01%)	0 (0.00%)	Yes
10. To consider and approve the amendments to and/or adoption of each of the following:				
i. the "Rules of Procedures of Shareholders' General Meeting";	369,679,700 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
ii. the "Rules of Procedures for the Board of Directors";	369,679,700 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
iii. the "Rules of Procedures for the Board of Supervisors"	369,679,700 (100.00%)	0 (0.00%)	0 (0.00%)	Yes

As more than two-thirds of the votes from the Shareholders (including their proxies) attending the EGM, with voting rights, were cast in favor of the resolutions numbered 1 to 10 above, resolutions numbered 1 to 10 were duly passed.

Ordinary Resolutions	Number of Votes (%)			Passed by Shareholders
	For	Against	Abstain	
11. To consider and approve the proposed engagement of intermediaries, including but not limited to China International Capital Corporation Limited (中國國際金融股份有限公司) as the sponsor/lead underwriter, Zhong Lun Law Firm (北京市中倫律師事務所) as the legal adviser to the Company as to PRC laws, and KPMG Huazhen LLP (畢馬威華振會計師事務所 (特殊普通合夥)) as the auditor, for the Issue of A Shares and listing on the Sci-Tech Board;	369,679,700 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
12. To consider and approve the amendments to and/or adoption of each of the following:				
i. the “Working System for Independent Non-Executive Directors”;	369,679,700 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
ii. the “Measures for the Administration of Related Transactions”;	369,679,700 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
iii. the “Measures for the Administration of External Guarantees”;	369,679,700 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
iv. the “Measures for the Administration of Outbound Investment”;	369,679,700 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
v. the “Management System for Standardizing Financial Transactions with Affiliates”	366,742,820 (99.21%)	0 (0.00%)	2,936,880 (0.79%)	Yes
vi. the “Administration Measures for the Use of Raised Funds” and implement a Special Account Storage System for the Proceeds;	366,742,820 (99.21%)	0 (0.00%)	2,936,880 (0.79%)	Yes
13. To consider and approve the confirmation of the Company’s related party transactions from 2020 to 2022 and the Company’s expected daily related party transaction in 2023;	63,608,140 (99.96%)	28,000 (0.04%)	0 (0.00%)	Yes
14. To consider and approve the proposed guarantee for bank credit facilities for wholly owned subsidiary.	369,679,700 (100.00%)	0 (0.00%)	0 (0.00%)	Yes

As more than half of the votes from the Shareholders (including their proxies) attending the EGM, with voting rights, were cast in favor of the resolutions numbered 11 to 14 above, resolutions numbered 11 to 14 were duly passed.

(II) Poll Results of the Class Meeting of H Shareholders

The poll results of the Class Meeting of H Shareholders were as follows:

Special Resolutions	Number of Votes (%)			Passed by Shareholders
	For	Against	Abstain	
1. To consider and approve the Issue of A Shares as follows (each and every items as a separate resolution)				
i. Class of new Shares to be issued;	81,063,200 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
ii. Place of listing;	81,063,200 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
iii. Nominal value of new Shares to be issued;	81,063,200 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
iv. Issue size;	81,063,200 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
v. Target subscribers;	81,063,200 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
vi. Method of issuance;	81,063,200 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
vii. Method of underwriting;	81,063,200 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
viii. Pricing methodology;	81,063,200 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
ix. Schedule of issuance;	79,396,580 (97.94%)	0 (0.00%)	1,666,620 (2.06%)	Yes
x. Use of Proceeds	81,063,200 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
xi. Validity period of the resolutions	81,063,200 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
2. To consider and approve the authorization the Board of Directors and persons authorized by it to fully handle relevant matters in connection with Issue of A Shares and listing on the Sci-Tech Board;	81,063,200 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
3. To consider and approve the investment projects to be funded by the proceeds raised from the Issue of A Shares and feasibility analysis (each and every items as a separate resolution):				
i. Drug early development service platform construction project	79,950,440 (98.63%)	0 (0.00%)	1,112,760 (1.37%)	Yes
ii. Antibody drug development and evaluation project	78,126,320 (96.38%)	0 (0.00%)	2,936,880 (3.62%)	Yes
iii. Preclinical and clinical development	81,063,200 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
iv. Supplementary working capital	81,063,200 (100.00%)	0 (0.00%)	0 (0.00%)	Yes

Special Resolutions	Number of Votes (%)			Passed by Shareholders
	For	Against	Abstain	
4. To consider and approve the proposal for the plan for undertaking accumulated unrecovered losses prior to the Issue of A Shares;	81,063,200 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
5. To consider and approve the share price stabilization plan within three years after the Company's initial public offering of A Shares and listing on the Sci-Tech Board;	81,063,200 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
6. To consider and approve the three-year dividend distribution plan for Shareholders after the initial public offering of A Shares and listing on the Sci-Tech Board;	73,123,760 (90.21%)	0 (0.00%)	7,939,440 (9.79%)	Yes
7. To consider and approve the impact of dilution on immediate return by the initial public offering of A Share and recovery measures for the immediate return;	79,396,580 (97.94%)	0 (0.00%)	1,666,620 (2.06%)	Yes
8. To consider and approve the undertakings and restraining measures relating to Issue of A Shares and listing on the Sci-Tech Board;	73,123,760 (90.21%)	0 (0.00%)	7,939,440 (9.79%)	Yes
9. To consider and approve the proposed amendments to the Articles in respect of Issue of A Shares.	81,035,200 (99.97%)	28,000 (0.03%)	0 (0.00%)	Yes

As more than two-thirds of the votes from the H Shareholders (including their proxies) attending the Class Meeting of H Shareholders, with voting rights, were cast in favor of the resolutions above, these resolutions were duly passed.

(III) Poll Results of the Class Meeting of Domestic and Unlisted Shareholders

The poll results of the Class Meeting of Domestic and Unlisted Shareholders were as follows:

Special Resolutions	Number of Votes (%)			Passed by Shareholders
	For	Against	Abstain	
1. To consider and approve the Issue of A Shares as follows (each and every items as a separate resolution):				
i. Class of new Shares to be issued;	288,616,500 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
ii. Place of listing;	288,616,500 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
iii. Nominal value of new Shares to be issued;	288,616,500 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
iv. Issue size;	288,616,500 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
v. Target subscribers;	288,616,500 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
vi. Method of issuance;	288,616,500 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
vii. Method of underwriting;	288,616,500 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
viii. Pricing methodology;	288,616,500 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
ix. Schedule of issuance;	288,616,500 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
x. Use of proceeds;	288,616,500 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
xi. Validity period of the resolutions;	288,616,500 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
2. To consider and approve the authorization the Board of Directors and persons authorized by it to fully handle relevant matters in connection with Issue of A Shares and listing on the Sci-Tech Board;	288,616,500 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
3. To consider and approve the investment projects to be funded by the proceeds raised from the Issue of A Shares and feasibility analysis (each and every items as a separate resolution):				
i. Drug early development service platform construction project	288,616,500 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
ii. Antibody drug development and evaluation project	288,616,500 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
iii. Preclinical and clinical development	288,616,500 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
iv. Supplementary working capital	288,616,500 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
4. To consider and approve the proposal for the plan for undertaking accumulated unrecovered losses prior to the Issue of A Shares;	288,616,500 (100.00%)	0 (0.00%)	0 (0.00%)	Yes

Special Resolutions	Number of Votes (%)			Passed by Shareholders
	For	Against	Abstain	
5. To consider and approve the share price stabilization plan within three years after the Company's initial public offering of A Shares and listing on the Sci-Tech Board;	288,616,500 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
6. To consider and approve the three-year dividend distribution plan for Shareholders after the initial public offering of A Shares and listing on the Sci-Tech Board;	288,616,500 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
7. To consider and approve the impact of dilution on immediate return by the initial public offering of A Share and recovery measures for the immediate return;	288,616,500 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
8. To consider and approve the undertakings and restraining measures relating to Issue of A Shares and listing on the Sci-Tech Board;	288,616,500 (100.00%)	0 (0.00%)	0 (0.00%)	Yes
9. To consider and approve the proposed amendments to the Articles in respect of Issue of A Shares.	288,616,500 (100.00%)	0 (0.00%)	0 (0.00%)	Yes

As more than two-thirds of the votes from the Domestic and Unlisted Shareholders (including their proxies) attending the Class Meeting of Domestic and Unlisted Shareholders, with voting rights, were cast in favor of the resolutions above, these resolutions were duly passed.

By order of the Board
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Shen Yuelel
*Chairman of the Board, Chief Executive Officer and
Executive Director*

Hong Kong, 20 April 2023

As at the date of this announcement, the board of directors of the Company comprises Dr. Shen Yuelel as chairman, chief executive officer and executive Director, Dr. Ni Jian and Dr. Zhang Haichao as executive Directors; Mr. Wei Yiliang, Dr. Zhou Kexiang and Ms. Zhang Leidi as non-executive Directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive Directors.